Deceptive Marketing: Reckitt Deposits PKR 30 Million Penalty Imposed by CCP in Strepsils Case.

Enforcing strict regulatory compliance and consumer protection laws, the Competition Commission of Pakistan (CCP) has successfully recovered PKR 30 million from multi-national consumer goods giant Reckitt Benckiser Pakistan Limited.

The recovery follows a definitive ruling by the Competition Appellate Tribunal (CAT), which upheld an original CCP decision finding the pharmaceutical and consumer giant guilty of engaging in deceptive marketing practices regarding its popular lozenge brand, Strepsils.

Upholding Anti-Deceptive Marketing Frameworks

The multi-million rupee recovery marks a major development for corporate accountability in the country’s healthcare and over-the-counter retail markets. The state’s competition watchdog initiated the action after discovering misalignments between consumer expectations and actual product ingredients.

The core parameters and findings of the CCP investigation include:

• Misleading Product Classification: The foundational dispute centered on product positioning, where the lozenges were marketed as a medicinal cure for sore throats despite losing their registration as a drug.
• Ingredient Profile Discrepancies: The watchdog pointed out that the public was led to believe Strepsils still contained active pharmaceutical ingredients (APIs) capable of treating infections, when it was actually being manufactured as a non-medicinal confectionery item.
• Upholding Section 10: The Competition Appellate Tribunal affirmed that public distribution networks must run without deceptive labeling, directly validating the CCP’s powers under Section 10 of the Competition Act.
• Immediate Compliance Action: Following the final legal review, Reckitt Benckiser officially deposited the full PKR 30 million fine into the commission’s designated accounts.

Reinforcing Fair Competition and Consumer Transparency

“The recovery of this penalty sends a clear, unambiguous message to corporate boards across Pakistan. Multi-national and domestic brands alike must maintain absolute truth in labeling and advertising. Consumer safety and market transparency cannot be compromised for commercial positioning.”

Regulatory compliance analysts highlight that this enforcement action will likely push alternative pharmaceutical and consumer product manufacturers to thoroughly audit their marketing copies and packaging designs. By removing deceptive claims from high-velocity retail products, the CCP aims to secure a level playing field for honest market competitors while shielding general consumers from spending money under false premises.

About The Author